Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
1 finding from 1 review
Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib showed no clear difference in overall survival compared with lapatinib (low certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).
1 finding from 1 review
Specific adverse events: haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
1 finding from 1 review
Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Economic evaluation · women with persistent, recurrent, or metastatic cervical cancer
1 finding from 1 review
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
DMFT/DMFS index (dental caries experience) · People who use drugs (PWUD): methamphetamine, heroin, opiate, cannabis and cocaine users
Illicit drug use was associated with substantially higher odds of dental caries experience (DMFT) (pooled OR 4.11, 95% CI 2.07-8.15; 7 studies; high heterogeneity I2=90.5%; ungraded).
1 finding from 1 review
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · women having endometriosis surgery
Postsurgical medical therapy may leads to lower disease recurrence ≤ 12 months (dichotomous) compared with placebo or no medical therapy (low certainty).
1 finding from 1 review